Mereo and Focus Fund Announce Etigilimab partnership with MD Anderson

Written By Mukul Verma

Study to be Conducted at The University of Texas MD Anderson Cancer Center

Mukul Verma
Previous

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers--
Next

MD Anderson Brings Underdogs into the Fight Against Cancer with Cancer Focus Fund